Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice to attend the Extraordinary General Meeting of Elos Medtech AB (publ)

The shareholders of Elos Medtech AB (publ), corporate ID no. 556021-9650, headquartered in Gothenburg, are hereby invited to the Extraordinary General Meeting (the “EGM”) on Friday, 13 August 2021. In light of the ongoing Covid-19 pandemic Elos Medtech AB's EGM will be carried out through advance voting (postal voting) pursuant to temporary regulations. There will be no possibility to attend in person or by proxy at the EGM. Information about the resolutions adopted at the EGM will be published on 13 August 2021 as soon as the outcome of the vote is finally compiled. Right to

Metso Outotec to divest its Waste Recycling business

Metso Outotec Corporation’s press release on July 16, 2021, at 11:00 a.m. EESTMetso Outotec has signed an agreement to divest its Waste Recycling business line to Ahlström Capital, a family-owned investment company. Metso Outotec announced in October 2020 its decision to divest its Recycling business which comprises of the waste recycling and metal recycling business lines based on the company’s strategic focus on the aggregates and mining industries. The closing of the transaction is expected to take place during the fourth quarter of 2021.The parties have decided not to disclose the

Practical goals guide the development of Tokmanni’s sustainability

Tokmanni        Press release        16 July 2021 at 11:00 am Sustainability at Tokmanni arises from concrete actions which are part of everyone’s day-to-day work. These actions are monitored and developed in line with common goals. Sustainability work at Tokmanni is guided by the company’s recently updated sustainability strategy. Sustainable way of working and responsible operations are a strategic choice for Tokmanni. The company’s new strategy was published in the spring of 2021, and it sets the direction for the development of sustainability and corporate responsibility, as

LMK Group initiates reporting of food waste in own production

With the purpose of increasing the transparency of its operations, LMK Group initiates yearly reporting of food waste from its production facilities in the Nordic region. For the group’s brands Linas Matkasse (Sweden), Godtlevert (Norway), Adams Matkasse (Norway) and RetNemt (Denmark), the food waste amounted to 1.74 grams per meal in 2020, corresponding to 3.08 grams per SEK 100 in revenue. Minimizing the occurrence of food waste in the overall flow of food production is an important part of the group’s sustainability work. According to the Swedish Environmental Protection Agency,

Update regarding acquisition of Svenska Campingpärlor AB

In an Extra General Meeting on 15 July, the shareholders of Grönklittsgruppen AB (publ) approved the proposal to divest the company’s camping business, Svenska Campingpärlor AB and related assets, to the United Camping group of which First Camp Group AB is part. The acquiring company is outside of First Camp Group AB and its subsidiaries. The bond holders of First Camp Group AB will therefore not be directly affected by this transaction.More information about the proposed transaction can be found at https://news.cision.com/first-camp/r/major-merger-in-camping-industry--scandinavia-s-two-

Ework Group AB (publ) publishes Interim Report, January – June 2021: Best Q2 earnings to date

“Ework is reporting its best second quarter ever after a vigorous recovery on the consulting market. The positive revenue and profitability trend accentuated, and by June, the firm had nearly 11,000 consultants on assignment, the highest number ever. In the quarter, Verama surpassed 70,000 digitally processed tenders. After the pandemic-related downturn of 2020, we’ve now bounced back above 2019 levels, and earnings are the best to date for a comparable period. Accordingly, Ework has emerged stronger from the pandemic." Extract from CEO Zoran Covic’s commentary to the Interim Report.

Major merger in camping industry: Scandinavia’s two largest chains become one

Sweden’s and Scandinavia’s two largest camping chains – First Camp and Svenska Campingpärlor – are merging. The new combined chain comprises a total of 55 destinations in Scandinavia and will generate a turnover of almost SEK 700 million in a normal year.The camping industry is facing a bright future thanks to the staycation trend, which has been accelerated by the COVID-19 pandemic, and strong sales of caravans and motorhomes.  The revenue generated by First Camp’s Swedish destinations during both the Easter and Midsummer weekends in 2021 was the highest ever. Now begins the next

Flowscape reports strong growth in the UK market as offices reopens

The UK market is now slowly returning to normal after months of shutdown. As a result, Flowscape has seen a significant increase in order inflow in the UK. During Q2 order revenue reached 110, 000 GBP (SEK 1,3 MSEK) with yearly recurring revenue of 80,000 GDP (SEK 960,000)"It is clear that the interest in smart office solutions has increased. We see many new requests for our solutions when a new vision of office work has begun to emerge. The UK has previously been very traditional regarding its office environment, and this is the first time we are seeing a mainstream movement towards

AVTECH and Southwest Airlines enters agreement for trial evaluation of Aventus Enroute Winds service

AVTECH Sweden AB (publ) and Southwest Airlines have today entered into an agreement covering a 3-month trial evaluation of the Aventus Enroute Winds service, targeted to start in the fourth quarter of 2021. The agreement includes an optional transition to a 17-month commercial service contract in the first quarter of 2022 with an expected value in between 3.5 and 7 MSEK, dependent on number of flights and USD exchange rate. The Aventus Enroute Winds service provides, as an addition to the Aventus Descent Winds service already in use, highly accurate and tailored enroute wind information

Enersense has been chosen as the main contractor of the Soidinmäki wind farm

Enersense International PlcPress Release 16 July 2021 at 10.00 a.m.A subsidiary of Enersense International Plc, a provider of zero-emission energy solutions, Empower PN Oy, which operates in the business area of Power, has signed an agreement with Tuulivoimayhtiö Pohjoistuuli Oy group for construction of a wind farm in Soidinmäki, Saarijärvi. The wind farm in Soidinmäki consists of seven power plants and the construction begins in August 2021. The project will be completed by the end of 2022 according to plans. Enersense will provide construction of the wind farm’s roads and platforms,

Publishing of Stockmann’s Half year financial report for January–June 2021

STOCKMANN plc, Press release 16.7.2021 at 10:00 EET Stockmann plc will publish the Half year financial report for January–June 2021 on Friday, 23 July 2021 at 8:00 a.m. EET. The press and analyst briefing will be held on 23 July 2021 at 10:00 as a live webcast, that can be followed by this link  or on the address stockmanngroup.com.  The recording and presentation material are available on the company's website after the event. Further information:Stockmann Media DeskMon–Fri 9–16 EET

RLS GLOBAL AB (publ) INTERIM REPORT, Q2, 2021

APRIL 1[st] – JUNE 3O[th] · Net sales amounted to TSEK 244 (TSEK 739) · Earnings before interest and taxes (EBIT) amounted to MSEK 8,5 (MSEK -5,6) · Other income TSEK 15 429 (TSEK 281) · Earning per share before dilution at SEK SEK 0,13 (SEK-0,09) · Cash flow from operating activities amounted to MSEK -6,280 (MSEK-5 472) · Liquid assets at the end of the period MSEK 6,9 (MSEK 30,3) · Equity ratio was 87% (91%) JAN 1[st] – JUNE 3O[th] · Net sales amounted to TSEK 302 (TSEK 1 112) · Earnings before interest and taxes (EBIT) amounted to MSEK 2,2 (MSEK-9,5) ·

Episealer® Talus: Case report with 5-years’ follow-up data accepted for publication

Episurf Medical (NASDAQ: EPIS B) today announces that a case report with 5-years’ follow-up data of the very first Episealer® Talus patient has been accepted for publication in the peer-reviewed scientific journal Foot & Ankle Surgery: Techniques, Reports & Cases (Holz J., Ryd L., Kaiser R., Hollander K., van Dijk N., Schneider S., Treatment of an Osteochondral Lesions of the Talus with a novel Patient-specific Metallic Implant: A Case Report with 5-year Follow-up and Review of the Literature., Foot & Ankle Surgery: Techniques, Reports & Cases, 2021). The publication will appear in volume 1,

Buy-backs of shares of series B in Saab during week 27-28 2021

During the period 9 July – 15 July 2021, Saab AB (publ) (LEI code 549300ZHO4JCQQI13M69) has repurchased in total 236.000 own shares of series B (ISIN: SE0000112385) as part of the share buy-back programme initiated by the Board of Directors in order to secure delivery of shares to participants in Saab’s long-term Share Matching Plan, Performance Share Plan and Special Projects Incentive.The share buy-back programme, which Saab announced on 11 June 2021, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the Commission Delegated Regulation (EU)

BioStock: Iconovo receives order for nasal Covid-19 vaccine development

Earlier this year, two Swedish life science companies, Iconovo, which develops complete inhalation products, and ISR, which develops immunotherapies, came together to start working on an inhalable Covid-19 vaccine using Iconovo’s ICOone platform. Now, the two companies have announced another agreement, this time for developing a nasal application of the vaccine using Iconovo’s new version of ICOone, called ICOone Nasal. The new application will lead to a faster track through clinical studies and thus a quicker path to market for this much-needed therapy.Read the full article at biostock.se:

Interim Report 1 April – 30 June 2021

· Strong growth in key ratios – significant steps in the right direction · Sales growth of 230% – signs of a normalization within healthcare following the pandemic · Confirmed timetable for 510(k) application and several clinical milestones during H2 2021"We are continuing to establish a solid foundation for growth globally, and I can confidently say that based on the now available clinical results for the Episealer®, our operating environment is improving substantially. As the clinical acceptance for a mini-metal implant with excellent clinical results grows in the orthopaedic

Continued lower sales due to pandemic but some stabilization

Q2                                · Net sales reached SEK 6.1 (13.9) million. · Result after tax came in at SEK -19.7 (-11.7) million. · Earnings per share, basic and diluted, were SEK -0.14 (-0.08). · Cash and cash equivalents were SEK 64.8 (30.9) million. Significant events in Q1 ·Enzymatica’s sales in the quarter decreased compared with Q2 2020 because of the pandemic resulting in fewer common colds. However, the cold remedy market in Sweden and in other markets began to recover during the quarter. ·Enzymatica’s rights issue was completed on June 2nd and

Interim report January to June 2021

Press release, Sweden, Stockholm, July 16, 2021 TagMaster shows record sales with improved results Second quarter 2021 · Net sales increased during the second quarter by 29,2% to 88,9 MSEK (69,8) · Adjusted EBITDA increased during the second quarter by 68,9% to 10,7 MSEK (6,3), corresponding to an adjusted EBITDA margin by 12,0% (9,2) · Operating loss was 4,8 MSEK (-12,5) which correspond to operating margin of -5,3% (-18,2) · Profit for the period was 4,0 MSEK (-12,4) · Result per share was 0,27 (-0,85) SEK[1] · Cash flow from operating activities for the period

Interim Report 1 April - 30 June 2021

First quarter · Net sales increased by 17 percent and amounted to SEK 3,279 million (2,805). · Operating profit before amortisation of intangible non-current assets (EBITA) increased by 31 percent and amounted to SEK 402 million (306) corresponding to an EBITA margin of 12.3 percent (10.9). · Operating profit increased by 37 percent and amounted to SEK 332 million (243) corresponding to an operating margin of 10.1 percent (8.7). · Profit after tax increased by 36 percent and amounted to SEK 250 million (184) and earnings per share before/after dilution amounted to SEK 0.90 (0.

Episurf Medical: Expansion of the European sales organization

Episurf Medical (NASDAQ: EPIS B) today announces two additions to the European sales organization. JAMO Orthopaedics has been appointed agent for the Episealer® Knee and Episealer® Talus in certain areas in the UK. JAMO Orthopaedics is an orthopaedic distributor focusing on the Midlands, and acts as a distributor or agent for several global orthopaedic companies. JAMO Orthopaedic will work alongside Episurf Medicals existing sales force in the UK. “JAMO Orthopaedics are excited and proud to be working alongside Episurf in the UK. With an evermore need for patient specific implants to

Status on US FDA Advisory Committee for roxadustat

16 July 2021 07:00 BST Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease The Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 13 to 1 that the benefit-risk profile of roxadustat does not support approval for the treatment of anaemia in chronic kidney disease (CKD) in non-dialysis dependent (NDD) adult patients, and 12 to 2 that the benefit-risk profile of roxadustat does not support approval for the treatment of anaemia in CKD in dialysis-dependent (DD) adult patients. The FDA will

Getinge Interim Report January-June 2021: Strong recovery in products for surgery

“In total, sales increased by 3.6% organically compared with the second quarter 2020, and the order intake declined by 6.1% organically compared with 2020 when we received very large orders of advanced ICU ventilators”, says Mattias Perjos, President & CEO. “Cash flow remained strong and net debt in relation to EBITDA improved further”.The second quarter was characterized by a rapidly growing need for cardiovascular surgery products in North America and acute needs for advanced ICU ventilators in India to treat COVID-19 patients. In addition, the high delivery rate of Getinge’s world-

REPORT ON THE SECOND QUARTER 2021

ALL-TIME HIGH SALES AND EBIT SECOND QUARTER 2021 · Net sales were SEK 5,571 m (3,329); an increase of · 67%, of which 66% was organic growth. · Operating profit before depreciation and amortization (EBITDA) was SEK 1,100 m (504), representing a margin of 19.8% (15.1%). · Operating profit (EBIT) before items affecting comparability was SEK 955 m (361), representing a margin of 17.2% (10.9%). · Items affecting comparability were SEK -58 m (-61) · Operating profit (EBIT) was SEK 898 m (300), representing a margin of 16.1% (9.0%). · Profit for the quarter was SEK 560 m

Elos Medtech Interim Report January 1 - June 30, 2021

A STRONG QUARTER WITH CONTINUED GROWTH April - June 2021 · Net sales for the second quarter amounted to SEK 181.0 (118.3) million, an increase of 53 percent compared with the same period last year. Net sales in local currencies increased by 63 percent. · Operating profit amounted to SEK 26.5 (14.9) million, corresponding to an operating margin of 14.7 (12.6) percent. In the second quarter of last year government grant and subsidies due to Covid-19 had a positive impact of SEK 38.9 million on operating profit. · Earnings after net financial items amounted to SEK 22.8 (9.1)

There are no items matching the current filter
There are no more items matching the current filter
Back to top